- Home
- SNES vs DARE Comparison
SNES vs DARE Comparison
Compare SNES & DARE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SNES
- DARE
- Stock Information
- Founded
- SNES 2004
- DARE 2015
- Country
- SNES United States
- DARE United States
- Employees
- SNES N/A
- DARE N/A
- Industry
- SNES Agricultural Chemicals
- DARE Biotechnology: Pharmaceutical Preparations
- Sector
- SNES Industrials
- DARE Health Care
- Exchange
- SNES Nasdaq
- DARE Nasdaq
- Market Cap
- SNES 24.0M
- DARE 25.1M
- IPO Year
- SNES 2016
- DARE N/A
- Fundamental
- Price
- SNES $2.72
- DARE $1.80
- Analyst Decision
- SNES Strong Buy
- DARE Strong Buy
- Analyst Count
- SNES 1
- DARE 2
- Target Price
- SNES $10.00
- DARE $10.00
- AVG Volume (30 Days)
- SNES 78.6K
- DARE 109.7K
- Earning Date
- SNES 11-10-2025
- DARE 11-13-2025
- Dividend Yield
- SNES N/A
- DARE N/A
- EPS Growth
- SNES N/A
- DARE N/A
- EPS
- SNES N/A
- DARE N/A
- Revenue
- SNES $2,301,000.00
- DARE N/A
- Revenue This Year
- SNES $49.17
- DARE $5,401.89
- Revenue Next Year
- SNES $89.89
- DARE $6,257.18
- P/E Ratio
- SNES N/A
- DARE N/A
- Revenue Growth
- SNES 39.37
- DARE N/A
- 52 Week Low
- SNES $1.30
- DARE $1.76
- 52 Week High
- SNES $6.24
- DARE $9.19
- Technical
- Relative Strength Index (RSI)
- SNES 32.29
- DARE 38.87
- Support Level
- SNES $2.60
- DARE $1.76
- Resistance Level
- SNES $3.40
- DARE $2.01
- Average True Range (ATR)
- SNES 0.28
- DARE 0.12
- MACD
- SNES -0.03
- DARE -0.00
- Stochastic Oscillator
- SNES 16.85
- DARE 24.73
About SNES SenesTech Inc.
SenesTech Inc is a United States-based biotech platform and research company engaged in developing technology for managing animal pest populations through fertility control. The company provides its solutions to the animal market, commercial markets, and food markets. It currently has two product lines of fertility control products: ContraPest and Evolve.
About DARE Dare Bioscience Inc.
Dare Bioscience Inc is a biopharmaceutical company committed to advancing products for women's health. The company identifies, develops, and brings to market a diverse portfolio of differentiated therapies that prioritize women's health and well-being, expand treatment options, and improve outcomes, in the areas of contraception, fertility, and vaginal and sexual health. The company's first product, XACIATO is a single-dose vaginal gel prescription product for the treatment of bacterial vaginosis in females 12 years of age and older. The company's portfolio includes two product candidates in clinical development namely, Ovaprene and Sildenafil Cream. It has one operating segment, women's health.